Steven Ross Johnson

Gene therapies offer sickle cell cure, but few can access them

Casgevy and Lyfgenia can eliminate severe pain crises, yet high costs, demanding treatment and specialist shortages leave thousands unable to reach the breakthrough.

CNBC · 3m